Interim report Q1, 2024: Strong growth in APAC and solid margins
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Vitrolife AB (publ) reported a first-quarter sales of SEK 841 million with flat growth in local currencies but a 2% decrease in SEK. Sales in APAC grew by 19%, while EMEA and Americas saw declines. Gross margin increased to 57.1%, EBITDA margin to 32.4%, and operating cash flow to SEK 198 million. Net income rose to SEK 115 million. The company restructured its business areas, with Genomics now part of Genetics. CEO Bronwyn Brophy O´Connor highlighted strong growth in APAC and solid margins.
Vitrolife AB (publ) ha segnalato vendite per il primo trimestre di 841 milioni di SEK, con una crescita stagnante nelle valute locali e una diminuzione del 2% in SEK. Le vendite in APAC sono aumentate del 19%, mentre in EMEA e nelle Americhe si sono registrate diminuzioni. Il margine lordo è salito al 57,1%, il margine EBITDA al 32,4% e il flusso di cassa operativo a 198 milioni di SEK. L'utile netto è aumentato a 115 milioni di SEK. L'azienda ha riorganizzato le sue aree di business, inserendo Genomics in Genetics. L'amministratore delegato Bronwyn Brophy O'Connor ha evidenziato una forte crescita in APAC e margini solidi.
Vitrolife AB (publ) reportó ventas del primer trimestre de 841 millones de SEK, con un crecimiento nulo en monedas locales pero una disminución del 2% en SEK. Las ventas en APAC crecieron un 19%, mientras que en EMEA y América se observaron descensos. El margen bruto aumentó al 57,1%, el margen de EBITDA al 32,4% y el flujo de caja operativo a 198 millones de SEK. El ingreso neto subió a 115 millones de SEK. La compañía reestructuró sus áreas de negocio, integrando Genomics en Genetics. La CEO Bronwyn Brophy O'Connor destacó el fuerte crecimiento en APAC y los márgenes sólidos.
Vitrolife AB (publ)는 첫 분기에 841백만 SEK의 매출을 보고했으며, 현지 통화로는 성장이 정체되었지만 SEK로는 2% 감소했습니다. APAC 지역의 매출은 19% 증가했지만, EMEA와 아메리카 지역은 감소했습니다. 총 마진은 57.1%로 증가했고, EBITDA 마진은 32.4%, 운영 현금 흐름은 198백만 SEK로 증가했습니다. 순이익은 115백만 SEK로 증가했습니다. 회사는 사업 영역을 개편하여 Genomics를 Genetics에 통합했습니다. CEO 브론윈 브로피 오코너는 APAC에서의 강력한 성장과 견고한 마진을 강조했습니다.
Vitrolife AB (publ) a rapporté des ventes de 841 millions de SEK pour le premier trimestre, avec une croissance nulle en monnaies locales mais une baisse de 2% en SEK. Les ventes en APAC ont augmenté de 19%, tandis que celles en EMEA et en Amériques ont diminué. La marge brute a augmenté à 57,1%, la marge d'EBITDA à 32,4% et le flux de trésorerie opérationnel à 198 millions de SEK. Le bénéfice net a atteint 115 millions de SEK. L'entreprise a restructuré ses domaines d'activité, avec Genomics désormais intégré à Genetics. La PDG Bronwyn Brophy O'Connor a souligné la forte croissance en APAC et des marges solides.
Vitrolife AB (publ) meldete für das erste Quartal einen Umsatz von 841 Millionen SEK, mit stagnierendem Wachstum in lokalen Währungen, jedoch einem Rückgang von 2% in SEK. Der Umsatz in APAC stieg um 19%, während er in EMEA und Amerika zurückging. Die Bruttomarge stieg auf 57,1%, die EBITDA-Marge auf 32,4% und der operative Cashflow auf 198 Millionen SEK. Der Nettogewinn stieg auf 115 Millionen SEK. Das Unternehmen restrukturierte seine Geschäftsbereiche, wobei Genomics nun Teil von Genetics ist. CEO Bronwyn Brophy O'Connor hob das starke Wachstum in APAC und die soliden Margen hervor.
Positive
- Sales in APAC grew by 19% in local currencies.
- Gross margin increased to 57.1%.
- Operating cash flow rose to SEK 198 million.
- Net income increased to SEK 115 million.
- Genomics is now part of Genetics business area.
- CEO emphasized strong growth in APAC and solid margins.
Negative
- None.
First quarter
- Sales of
SEK 841 (854) million, a flat growth in local currencies and a decrease of2% in SEK. - Sales per region, in local currencies was +
19% in APAC, -2% in EMEA and -14% inAmericas . - Sales per business area, in local currencies was +
12% in Consumables, +8% in Technologies and -12% in Genetics. - Gross margin increased to
57.1% (56.8). - Operating income before depreciation and amortisation (EBITDA) increased to
SEK 272 (262) million, giving an EBITDA margin of32.4% (30.6). - Operating cash flow increased to
SEK 198 million (160). - Net income was
SEK 115 (99) million, resulting in earnings per share ofSEK 0.85 (0.74). - The product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 18-04-2024 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q1, 2024 |
View original content:https://www.prnewswire.com/news-releases/interim-report-q1-2024-strong-growth-in-apac-and-solid-margins-302120652.html
SOURCE Vitrolife AB (publ)
Vitrolife AB (publ) reported first-quarter sales of SEK 841 million.
Sales in APAC grew by 19% in local currencies.
The gross margin increased to 57.1%.
Operating cash flow rose to SEK 198 million.
Net income rose to SEK 115 million.
Genomics is now part of the Genetics business area.
Bronwyn Brophy O´Connor is the CEO of Vitrolife AB (publ).
VITROLIFE AB UNSP/ADR
OTC:VTRLY
VTRLY Rankings
VTRLY Latest News
Apr 4, 2024
Conference call interim report
VTRLY Stock Data
2.23B
75.00M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
Goteborg